Advances in systemic treatment options for brain metastases in HER2-positive breast cancer
10.3781/j.issn.1000-7431.2024.2304-0174
- VernacularTitle:HER2阳性乳腺癌脑转移系统治疗选择研究进展
- Author:
Ye WANG
1
;
Xichun HU
Author Information
1. 复旦大学附属肿瘤医院肿瘤内科,上海 200000
- Keywords:
Human epidermal growth factor receptor 2-positive breast cancer;
Brain metastasis;
Systemic treatment;
Blood-brain barrier;
Blood-tumor barrier
- From:
Tumor
2024;44(1):1-12
- CountryChina
- Language:Chinese
-
Abstract:
Patients with human epidermal growth factor receptor 2(HER2)-positive breast cancer are prone to develop brain metastases.Inefficient drug delivery due to the blood-brain barrier/blood-tumor barrier is a major dilemma in the systemic treatment of brain metastases.Therefore,patients with HER2-positive breast cancer brain metastasis usually have few treatment options and poor prognosis.In traditional opinions,it is difficult for macromolecule drugs to cross the blood-brain barrier,but with the in-depth understanding of the properties of the blood-brain barrier/blood-tumor barrier,this view has gradually changed,especially when several clinical studies have validated the efficacy of new antibody-drug conjugates(ADC)in patients with brain metastasis in the recent years.These findings have provided more treatment options for HER2-positive breast cancer patients with brain metastasis.This review introduces the mechanism of systemic treatment drugs and sorts out the current important advances in systemic treatment for HER2-positive breast cancer patients with brain metastases,hoping to provide some reference for the clinical practice of treatment for HER2-positive breast cancer brain metastases in China.
